Robert J. Dow

Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

biolitec Pharma Ltd. produces and markets a photo technology platform for the treatment of head and neck cancer. Its product Foscan, is a porphyrin photosensitising device used for the treatment of head and neck cancer in patients who cannot be treated with other therapies. The company is headquartered in Dublin, Ireland.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.